S&P 500   5,036.95 (+1.40%)
DOW   38,433.44 (+1.18%)
QQQ   420.20 (+1.34%)
AAPL   167.03 (+1.23%)
MSFT   401.32 (+0.55%)
META   485.52 (+0.93%)
GOOGL   157.22 (+2.03%)
AMZN   177.36 (+1.56%)
TSLA   142.30 (-3.23%)
NVDA   798.20 (+4.75%)
AMD   149.24 (+1.77%)
NIO   4.03 (+6.05%)
BABA   70.65 (+2.29%)
T   16.34 (-1.03%)
F   12.88 (+6.10%)
MU   109.33 (+2.40%)
GE   151.49 (+2.32%)
CGC   8.02 (+1.13%)
DIS   113.38 (+0.68%)
AMC   3.39 (+7.28%)
PFE   26.47 (+1.81%)
PYPL   63.47 (+1.86%)
XOM   121.36 (+1.23%)
S&P 500   5,036.95 (+1.40%)
DOW   38,433.44 (+1.18%)
QQQ   420.20 (+1.34%)
AAPL   167.03 (+1.23%)
MSFT   401.32 (+0.55%)
META   485.52 (+0.93%)
GOOGL   157.22 (+2.03%)
AMZN   177.36 (+1.56%)
TSLA   142.30 (-3.23%)
NVDA   798.20 (+4.75%)
AMD   149.24 (+1.77%)
NIO   4.03 (+6.05%)
BABA   70.65 (+2.29%)
T   16.34 (-1.03%)
F   12.88 (+6.10%)
MU   109.33 (+2.40%)
GE   151.49 (+2.32%)
CGC   8.02 (+1.13%)
DIS   113.38 (+0.68%)
AMC   3.39 (+7.28%)
PFE   26.47 (+1.81%)
PYPL   63.47 (+1.86%)
XOM   121.36 (+1.23%)
S&P 500   5,036.95 (+1.40%)
DOW   38,433.44 (+1.18%)
QQQ   420.20 (+1.34%)
AAPL   167.03 (+1.23%)
MSFT   401.32 (+0.55%)
META   485.52 (+0.93%)
GOOGL   157.22 (+2.03%)
AMZN   177.36 (+1.56%)
TSLA   142.30 (-3.23%)
NVDA   798.20 (+4.75%)
AMD   149.24 (+1.77%)
NIO   4.03 (+6.05%)
BABA   70.65 (+2.29%)
T   16.34 (-1.03%)
F   12.88 (+6.10%)
MU   109.33 (+2.40%)
GE   151.49 (+2.32%)
CGC   8.02 (+1.13%)
DIS   113.38 (+0.68%)
AMC   3.39 (+7.28%)
PFE   26.47 (+1.81%)
PYPL   63.47 (+1.86%)
XOM   121.36 (+1.23%)
S&P 500   5,036.95 (+1.40%)
DOW   38,433.44 (+1.18%)
QQQ   420.20 (+1.34%)
AAPL   167.03 (+1.23%)
MSFT   401.32 (+0.55%)
META   485.52 (+0.93%)
GOOGL   157.22 (+2.03%)
AMZN   177.36 (+1.56%)
TSLA   142.30 (-3.23%)
NVDA   798.20 (+4.75%)
AMD   149.24 (+1.77%)
NIO   4.03 (+6.05%)
BABA   70.65 (+2.29%)
T   16.34 (-1.03%)
F   12.88 (+6.10%)
MU   109.33 (+2.40%)
GE   151.49 (+2.32%)
CGC   8.02 (+1.13%)
DIS   113.38 (+0.68%)
AMC   3.39 (+7.28%)
PFE   26.47 (+1.81%)
PYPL   63.47 (+1.86%)
XOM   121.36 (+1.23%)

Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis

$24.41
+0.60 (+2.52%)
(As of 02:10 PM ET)
Today's Range
$23.75
$24.51
50-Day Range
$23.57
$29.93
52-Week Range
$23.29
$35.56
Volume
84,964 shs
Average Volume
560,774 shs
Market Capitalization
$1.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.70

Mirum Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.11 Rating Score
Upside/​Downside
112.9% Upside
$51.70 Price Target
Short Interest
Bearish
17.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.69
Upright™ Environmental Score
News Sentiment
0.32mentions of Mirum Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$130,267 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.29) to $0.63 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.27 out of 5 stars

Medical Sector

133rd out of 907 stocks

Pharmaceutical Preparations Industry

43rd out of 428 stocks

MIRM stock logo

About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

MIRM Stock Price History

MIRM Stock News Headlines

BUY ALERT: Billionaires piling into this asset class
Legendary investor Warren Buffett has poured over $500 million into gold! It's a BIG move by one of the world's most cautious investors.
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up to $24.01
BUY ALERT: Billionaires piling into this asset class
Legendary investor Warren Buffett has poured over $500 million into gold! It's a BIG move by one of the world's most cautious investors.
Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares
MIRM Mar 2024 40.000 call
See More Headlines
Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/22/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MIRM
Fax
N/A
Employees
264
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$51.70
High Stock Price Target
$72.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+117.1%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

Net Income
$-163,410,000.00
Pretax Margin
-87.15%

Debt

Sales & Book Value

Annual Sales
$186.37 million
Book Value
$5.33 per share

Miscellaneous

Free Float
35,694,000
Market Cap
$1.12 billion
Optionable
Optionable
Beta
1.14
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Christopher PeetzMr. Christopher Peetz (Age 45)
    CEO & Director
    Comp: $1.09M
  • Mr. Peter Radovich M.B.A. (Age 46)
    Ph.D., COO & President
    Comp: $732.15k
  • Dr. Pamela Vig Ph.D. (Age 53)
    Chief Scientific Officer & Head of Research
    Comp: $678.2k
  • Ms. Lara Longpre MBA (Age 54)
    MSC, Chief Development Officer
    Comp: $678.2k
  • Mr. Eric H. Bjerkholt M.B.A. (Age 64)
    Chief Financial Officer
  • Andrew McKibben
    Vice President of Investor Relations and Finance
  • Mr. Paul K. Ross
    Chief Compliance Officer
  • Ms. Erin Campany (Age 56)
    Senior Vice President of Human Resources
  • Dr. Ian Clements Ph.D. (Age 55)
    Consultant
    Comp: $649.1k
  • Ms. Vinita P. Kumar
    Senior vice President of Quality

MIRM Stock Analysis - Frequently Asked Questions

Should I buy or sell Mirum Pharmaceuticals stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MIRM shares.
View MIRM analyst ratings
or view top-rated stocks.

What is Mirum Pharmaceuticals' stock price target for 2024?

9 analysts have issued 1-year price targets for Mirum Pharmaceuticals' stock. Their MIRM share price targets range from $35.00 to $72.00. On average, they anticipate the company's stock price to reach $51.70 in the next twelve months. This suggests a possible upside of 112.9% from the stock's current price.
View analysts price targets for MIRM
or view top-rated stocks among Wall Street analysts.

How have MIRM shares performed in 2024?

Mirum Pharmaceuticals' stock was trading at $29.52 at the beginning of the year. Since then, MIRM stock has decreased by 17.8% and is now trading at $24.28.
View the best growth stocks for 2024 here
.

When is Mirum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MIRM earnings forecast
.

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) posted its earnings results on Wednesday, February, 28th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.32. The company earned $69.55 million during the quarter, compared to analyst estimates of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative trailing twelve-month return on equity of 66.24%.

What ETFs hold Mirum Pharmaceuticals' stock?

ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and Virtus LifeSci Biotech Products ETF (BBP).First Trust Innovation Leaders ETF (ILDR).

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).

When did Mirum Pharmaceuticals IPO?

Mirum Pharmaceuticals (MIRM) raised $75 million in an IPO on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Who are Mirum Pharmaceuticals' major shareholders?

Mirum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.14%), Los Angeles Capital Management LLC (0.09%), Wealth Enhancement Advisory Services LLC (0.07%) and Allspring Global Investments Holdings LLC (0.04%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich.
View institutional ownership trends
.

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MIRM) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners